VITAL DIAGNOSTICS acquired by ELITECH GROUP
Context
Instead of a simple territorial expansion, this cross-border maneuver acts as a catalyst for ELITech Group’s "300 Million Euro" roadmap, fundamentally rebalancing its geographic revenue split. By capturing Vital Diagnostics, the group secures a turnkey infrastructure for the US physician office laboratory market while gaining an immediate foothold in the Australian and New Zealand clinical sectors. The strategic rationale centers on the industrial synergy between the target’s benchtop analyzer expertise and the group's established chemical reagent pipeline.
VITAL DIAGNOSTICS, which reported an EBITDA margin of [members only] in 2012, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Vital Diagnostics operates as a premier technology organization dedicated to the engineering and distribution of clinical chemistry analyzers and specialized reagents. The entity’s business model is centered on a proprietary framework of benchtop diagnostic systems specifically designed for the physician office laboratory (POL), small-to-medium-sized hospitals, and specialized clinics. Its value proposition is anchored in technical operational depth, providing integrated hardware and chemical assay solutions that facilitate decentralized medical testing. Strategically, the firm focuses on the "near-patient" testing niche, ensuring that diagnostic results are both rapid and accurate within primary care settings. By maintaining a specialized focus on clinical chemistry and hematology, the organization ensures a mission-critical role in the structural efficiency of laboratory workflows across North America and Australasia. The entity prioritizes manufacturing quality and technical support to facilitate the structural advancement of community-based healthcare diagnostics.
Ent. Value
$25–50M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (USD)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 08/2012 | BC PARTNERS | AENOVA GROUP | GERMANY | CDMO |
| 05/2011 | AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 09/2010 | SPARRING CAPITAL | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 09/2009 | THE CARLYLE GROUP | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 04/2007 | ASTORG | ETHYPHARM | FRANCE | Pharma & Biotech |
| 01/2006 | EDMOND DE ROTHSCHILD CAPITAL PARTNERS | ACTEON | FRANCE | Medical Devices |
Other operations with ELITECH GROUP
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 05/2024 | BRUKER | ELITECH GROUP | FRANCE | Diagnostic Equipment |
| 05/2017 | PAI PARTNERS | ELITECH GROUP | FRANCE | Diagnostic Equipment |
REFERENCES
Revenue range: $25–50M
EBITDA range: $0–5M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VITAL DIAGNOSTICS by ELITECH GROUP are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.